| 4 | 1/1 | 返回列表 |
| 查看: 776 | 回復(fù): 3 | ||
| 本帖產(chǎn)生 1 個 翻譯EPI ,點擊這里進行查看 | ||
霜葉金蟲 (小有名氣)
|
[求助]
求助一段摘要翻譯,謝謝
|
|
|
DESIGN: A retrospective cohort study: (Part I) cross-sectional, (Part II) longitudinal. SETTING AND PARTICIPANTS: PD patients at a Movement Disorders Center in a large academic, tertiary medical setting. OUTCOME MEASURES: An analysis was performed using carbidopa/levodopa at dosages below and above the 800 mg threshold. A secondary analysis was then performed using two consecutive clinic visits to determine the effects of crossing the 800 mg threshold. Comparisons were made on standardised scales. RESULTS: There was no significant difference in motor, mood and quality-of-life scores in patients consuming below and above the 800 mg carbidopa/levodopa threshold, though a mild worsening in dyskinesia duration was noted without worsening in dyskinesia pain and disability. In PD patients who crossed the 800 mg threshold between two consecutive clinic visits, a significant improvement in depressive symptoms and quality-of-life measures was demonstrated, and in these patients there was no worsening of motor fluctuations or dyskinesia. CONCLUSIONS: The data suggest that PD patients have the potential for enhanced clinical benefits when eclipsing the 800 mg carbidopa/levodopa threshold. Many patients will likely need to eclipse the 800 mg threshold and pharmacies and insurance companies should be aware of the requirements that may extend beyond approval limits. |
|
設(shè)計: 回顧性隊列研究:(第1部分)橫向,(第2部分)縱向。 設(shè)置和參與者: 運動障礙中心接受治療的帕金森病患者,大型學(xué)術(shù),三級醫(yī)療環(huán)境。 結(jié)局觀測指標: 分析實施使用的卡比多巴/左旋多巴的劑量低于和高于800 mg閾值。隨后實施二次分析,使用連續(xù)2次門診訪視,以確定跨越800 mg閾值的影響。穿越800毫克門檻。比較在標準化單位基礎(chǔ)上進行。 結(jié)果: 服用低于與高于800 mg卡比多巴/左旋多巴閾值的患者之間的運動、情緒和生活質(zhì)量分數(shù)并無顯著差異,但觀察到了運動障礙持續(xù)時間略微延長,未觀察到運動障礙疼痛和殘疾狀況惡化。連續(xù)2次門診訪視中交叉服用了800 mg閾值上、下劑量藥物的患者中,抑郁癥狀和生活質(zhì)量指標得到了顯著改善,這些患者中,未出現(xiàn)運動波動或運動障礙加重。 結(jié)論: 這些數(shù)據(jù)表明,當跨越800 mg卡比多巴/左旋多巴閾值劑量時,帕金森病患者所獲得的臨床收益有可能增加。很多患者可能需要跨越800 mg閾值劑量,藥店和保險公司應(yīng)該意識到這種可能超出了核準限度的需求。 |
|
設(shè)計: 回顧性隊列研究 第一部分)橫向, (第二部分)縱向。地點和對象: PD患者,大型學(xué)術(shù)運動障礙中心(三級醫(yī)療點)。 結(jié)果評價: 通過使用低于和高于800mg閾值的卡比多巴/左旋多巴劑量來進行一次分析。二次分析是通過連續(xù)兩次到醫(yī)院看病來確定超過800mg閾值的影響。我們對標準化尺度進行了比較。 結(jié)果: 當患者使用低于或高于800mg閾值的卡比多巴/左旋多巴時,患者在癥狀、情緒和生活質(zhì)量評分上都沒有明顯的差異,盡管運動障礙期間的輕微惡化是在運動障礙疼痛沒有惡化和沒有殘疾時記錄的。PD患者連續(xù)兩次到超過800mg閾值的醫(yī)院看病,證明其抑郁癥狀和生活質(zhì)量顯著改善,這些病人的癥狀波動或運動障礙沒有進一步惡化。 結(jié)論: 數(shù)據(jù)表明, 當卡比多巴/左旋多巴超過800mg閾值時,PD患者具有增強的臨床益處的潛力。許多患者可能需要超過的800mg閾值,同時藥店和保險公司應(yīng)該意識到這種的需求可能超出了審批限制。 |
| 4 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 考研調(diào)劑 +4 | Sanmu-124 2026-03-26 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 265求調(diào)劑 +5 | 小木蟲085600 2026-03-27 | 5/250 |
|
|
[考研] 272求調(diào)劑 +7 | 腳滑的守法公民 2026-03-27 | 7/350 |
|
|
[考研] 340求調(diào)劑 +4 | jhx777 2026-03-27 | 4/200 |
|
|
[考研] 085701環(huán)境工程,267求調(diào)劑 +9 | minht 2026-03-26 | 9/450 |
|
|
[考研] 308求調(diào)劑 +6 | 墨墨漠 2026-03-27 | 6/300 |
|
|
[考研] 0856調(diào)劑 +5 | 求求讓我有書讀?/a> 2026-03-26 | 6/300 |
|
|
[考研] 269專碩求調(diào)劑 +10 | 金恩貝 2026-03-21 | 10/500 |
|
|
[考研] 復(fù)試調(diào)劑,一志愿南農(nóng)083200食品科學(xué)與工程 +5 | XQTJZ 2026-03-26 | 5/250 |
|
|
[考研] 材料求調(diào)劑 +8 | @taotao 2026-03-21 | 8/400 |
|
|
[考研] 329求調(diào)劑 +7 | 鈕恩雪 2026-03-25 | 7/350 |
|
|
[考研] 一志愿 南京郵電大學(xué) 288分 材料考研 求調(diào)劑 +3 | jl0720 2026-03-26 | 3/150 |
|
|
[考研] 求調(diào)劑 +3 | QiMing7 2026-03-25 | 3/150 |
|
|
[考研] 考研一志愿蘇州大學(xué)初始315(英一)求調(diào)劑 +3 | sbdksD 2026-03-24 | 4/200 |
|
|
[考研] 各位老師您好:本人初試372分 +5 | jj涌77 2026-03-25 | 6/300 |
|
|
[考研] 284求調(diào)劑 +15 | Zhao anqi 2026-03-22 | 15/750 |
|
|
[考研] 086003食品工程求調(diào)劑 +6 | 淼淼111 2026-03-24 | 6/300 |
|
|
[考研] 求調(diào)劑一志愿武漢理工大學(xué)材料工程(085601) +5 | WW.' 2026-03-23 | 7/350 |
|
|
[考研] 336求調(diào)劑 +4 | 收到VS 2026-03-20 | 4/200 |
|
|
[考研] 0805材料320求調(diào)劑 +3 | 深海物語 2026-03-20 | 3/150 |
|